AUS
NZ
UK
CA
USA
IND
Healthcare
Avacta Group (LSE:AVCT) Shares Rise Above Key FTSE 350 Indicator
March 20, 2026 09:55 AM GMT| By Vivek SinghAvacta Group activity in FTSE 350 reflects biotechnology research, targeted drug delivery innovation, and share movement influenced by clinical progress and evolving healthcare sector dynamics.
Animalcare Group (LSE:ANCR) Falls Below Key Average in FTSE 350
March 20, 2026 09:40 AM GMT| By Vivek SinghAnimalcare Group reflects trading changes within the FTSE 350 Companies segment, focusing on veterinary healthcare, pharmaceutical development, and evolving trends in animal health markets.
HUTCHMED (LSE:HCM) Falls Below Key Average in FTSE AIM 100
March 20, 2026 08:42 AM GMT| By Vivek SinghHUTCHMED’s presence in the ftse aim 100 reflects advancements in oncology research, integrated pharmaceutical operations, and evolving market activity within the global biotechnology sector.
Healthcare Sector Movements Across FTSE 350
March 20, 2026 07:36 AM GMT| By Team Kalkine MediaHealthcare sector dynamics and institutional commentary shape the narrative around a major UK medical technology company within the FTSE index landscape.
Is FTSE 100 Pharma Stability Holding
March 18, 2026 04:29 PM GMT| By Team Kalkine MediaHighlights,Pharmaceutical sector dynamics continue shaping AstraZeneca’s role in UK markets,Global healthcare demand reinforces the company’s operational footprint,Index positioning reflects broader trends within the UK equity environment,The pharmac...
Is FTSE 350 signalling change?
March 18, 2026 04:29 PM GMT| By Team Kalkine MediaHighlights,Biotechnology sector activity draws renewed attention within the UK market landscape,Technical positioning sparks discussion across broader market sentiment,Sector-wide developments continue shaping narratives within established indices,Th...
_03_18_2026_12_58_17_073905.jpg)
Advanced Medical Solutions Group Quarterly Results Highlight
March 18, 2026 01:27 PM GMT| By Vivek SinghAdvanced Medical Solutions Group plc (LON:AMS) disclosed quarterly results, detailing key profitability metrics and operational data for the latest reporting period with significant product portfolio activity across surgical and wound‑care solutions.
Uniphar plc (LON:UPR) Slides on Low Volume in FTSE AIM 100
March 18, 2026 06:20 AM GMT| By Vivek SinghUniphar plc activity and healthcare services role examined within the ftse aim 100 index, highlighting operations, trading patterns, and industry context across European markets.
Lab-Grown Leather Breakthrough Lifts BSF Enterprise
March 18, 2026 05:26 AM GMT| By Vivek SinghBSF Enterprise advances lab-grown leather with eco-friendly tanning and scalable production, marking a key step toward sustainable materials adoption in global fashion and manufacturing industries.
AstraZeneca Expands Oncology Reach With Key Drug Advances
March 18, 2026 04:22 AM GMT| By Vivek SinghAstraZeneca advances oncology strategy with new drug approvals, expanding cancer treatment reach and reinforcing its presence across global markets while shaping long-term growth expectations.
Healthcare Sector Developments Stay in Focus in UK Equity Discussions
March 17, 2026 12:05 PM GMT| By Team Kalkine MediaHealthcare sector developments and institutional movements continue to shape UK market narratives, with global pharmaceutical activity influencing domestic index discussions.
BSF Enterprise Faces Setback as Funding Plan Shifts
March 17, 2026 07:33 AM GMT| By Vivek SinghBSF Enterprise revises its funding strategy, ends a planned capital raise, and explores new financing options while continuing to support its tissue engineering ventures.
Allergy Therapeutics (LSE:AGY) Shares Slip in FTSE 350 Index Trade
March 16, 2026 11:51 AM GMT| By Vivek SinghAllergy Therapeutics presence in the FTSE 350 reflects biotechnology research into allergy immunotherapy, diagnostic tools, and global distribution of treatments addressing allergic conditions.
AstraZeneca Outlook: Valuation Debate After Long Rally
March 15, 2026 05:50 PM GMT| By Vivek SinghA detailed look at AstraZeneca’s valuation debate, research pipeline strength, and long-term growth narrative as the pharmaceutical major continues to attract attention across the UK equity market.
AstraZeneca (LSE:AZN) Valuation Insights After Recent Price Moves
March 13, 2026 11:37 AM GMT| By Vivek SinghAstraZeneca (LSE:AZN) valuation draws attention as long-term growth trends and market dynamics shape investor interest, highlighting key risks and earnings potential in the healthcare sector.
BSF Enterprise Funding Update Echoes New Strategic Direction
March 13, 2026 11:16 AM GMT| By Vivek SinghInsightful overview of BSF Enterprise’s funding update and share movements, highlighting capital strategy and market context.
GSK Shifts Strategy with Strategic Licensing of Late‑Stage Drug
March 11, 2026 12:58 PM GMT| By Team Kalkine MediaExplore GlaxoSmithKline’s strategic licensing of a late‑stage liver disease drug, analyzing pipeline focus, partnerships, and implications for LSE & FTSE stock market trends in the UK.
AstraZeneca Strengthens Pipeline with Rare Disease and Oncology Wins
March 10, 2026 06:48 PM GMT| By Vivek SinghAstraZeneca (LSE:AZN) gains regulatory wins in rare disease and oncology, boosting its treatment reach and pipeline strength while advancing targeted therapies and late-stage programs.
AstraZeneca Gains Momentum With New Drug Review Advances
March 10, 2026 11:03 AM GMT| By Vivek SinghAstraZeneca records regulatory progress as Koselugo gains approval in Canada and ENHERTU receives Priority Review in the United States, highlighting growth in rare disease and oncology research programs.
Healthcare Focus Within FTSE AIM 100 Index Spotlight
March 10, 2026 09:35 AM GMT| By Team Kalkine MediaHealthcare technology focused on infection prevention remains an active topic within the UK market landscape as medical innovation companies operate within recognised equity benchmarks.
